-
Trader’s Buzz: Pharmacyclics Inc. (NASDAQ:PCYC), Magnum Hunter Resources Corp. (NYSE:MHR), Qihoo 360 Technology Co. (NYSE:QIHU), Atlantic American (NASDAQ:AAME), Providence Service (NASDAQ:PRSC)
Pharmacyclics, Inc. (NASDAQ:PCYC) announced that it has been awarded BayBio’s 2014 Pantheon DiNA™ Award for Outstanding Company for its rapid development and commercialization of IMBRUVICA® (ibrutinib). The award was presented at BayBio’s 11th Annual Pantheon DiNA Awards ceremony in San Francisco. Pharmacyclics Inc. (NASDAQ:PCYC) in last trading activity decreased -1.73% to close at $132.65. Company…
-
Morning Watch List: Pfizer Inc. (NYSE:PFE), Petroleo Brasileiro Petrobras SA (ADR) (NYSE:PBR-A), Cyrusone Inc. (NASDAQ:CONE), Vodafone Group Plc (ADR) (NASDAQ:VOD),), Pharmacyclics (NASDAQ:PCYC)
Pfizer Inc. (NYSE:PFE) and Merck & Co., Inc. (NYSE:MRK) recently announced global strategic alliance to enhance their respective presence in immune-oncology segment. Both the companies will work together towards the development and commercialization of Merck’s investigational therapy MSB0010718C, having potential for treatment of multiple tumor types. Pfizer Inc. (NYSE:PFE) in last trading activity increased 0.16%…
-
Stock Runners: Micron Technology (NASDAQ:MU), QUALCOMM (NASDAQ:QCOM), Pharmacyclics Inc. (NASDAQ:PCYC), Calix Inc. (NYSE:CALX), Spectra Energy Corp. (NYSE:SE)
On 27 October Micron Technology, Inc. (NASDAQ:MU) said that its board had authorized as much as $1 billion in share buybacks, its first such repurchases in three years. Micron Technology, Inc. (NASDAQ:MU) in last trading activity advanced 0.76% to close at $33.21. Company weekly performance is 0.82% while its quarterly performance stands at -0.24%. Micron…
-
Investors Watch List: Pharmacyclics Inc. (NASDAQ:PCYC), Altera Corp. (NASDAQ:ALTR), Blackhawk Network Holdings (NASDAQ:HAWK), The TJX Companies (NYSE:TJX), China Biologic Products (NASDAQ:CBPO)
Pharmacyclics Inc (NASDAQ:PCYC) COO Maky Zanganeh sold 30,482 shares of the stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $134.69, for a total transaction of $4,105,620.58. Following the sale, the chief operating officer now directly owns 210,312 shares in the company, valued at approximately $28,326,923. Pharmacyclics…
-
Stock Highlights: Johnson & Johnson (NYSE:JNJ), Synacor (NASDAQ:SYNC), Rockwell Automation Inc. (NYSE:ROK), Pharmacyclics Inc. (NASDAQ:PCYC), TIBCO Software Inc. (NASDAQ:TIBX)
On October 23, Johnson & Johnson (NYSE:JNJ) was found not liable by a Texas jury on Thursday in the first case to go to trial over whether Pinnacle hip implants made by the company’s DePuy Orthopedics unit were defective. The test case had high stakes for the pharmaceutical giant, which is hoping to avoid a…
-
Trader’s Watch List : iGATE (NASDAQ:IGTE), ServiceSource International (NASDAQ:SREV), Paychex, Inc. (NASDAQ:PAYX), Bob Evans Farms, Inc. (NASDAQ:BOBE), Pharmacyclics Inc. (NASDAQ:PCYC)
New Jersey-based IT services major iGate Corporation has announced a new facility in Noida near here that adds to its existing offices in the region and expands its presence in the region. iGATE Corporation (NASDAQ:IGTE) in last trading activity increased 0.05% to close at $37.98. Company weekly performance is 6.93% while its quarterly performance stands…
-
Large Cap Stocks: Pharmacyclics (PCYC), Under Armour (UA), Intuit (INTU)
Pharmacyclics, Inc. (NASDAQ:PCYC) beat quarterly EPS by $0.09 ($0.95 versus $0.86 estimate), revenues surged 113.1% year over year to $123.6 million versus $99.91 million estimate; target raised to $191 from $163 at JMP Securities following earnings. Shares of Pharmacyclics, Inc. (NASDAQ:PCYC) closed at $151.61 in last trading session. Yesterday share price of the company was…